Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review

References

• Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American college of Cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European heart rhythm association and the heart rhythm society. Circulation. 2006;114(7):e257–354.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008;92(1):17–40.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Centre for Reviews and Dissemination. Systematic Reviews. CRD’s guidance for undertaking reviews in health care. York: Univeristy of York; 2009. [ cited 2018 Apr 20] Available from: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf
   Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011. cited. 2018 Apr 20. Available from. http://handbook-5-1.cochrane.org/
   Google Scholar
• Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384.
   PubMed Web of Science ®Google Scholar
• Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015;114(6):1277–1289.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
   PubMed Web of Science ®Google Scholar
• Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014;30(12):2461–2469.
   PubMed Web of Science ®Google Scholar
• Chan YH, Kuo CT, Yeh YH, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2016;68(13):1389–1401.
   PubMed Web of Science ®Google Scholar
• Kodani E, Atarashi H, Inoue H, et al. Beneficial effect of non-vitamin k antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation – results of the J-RHYTHM Registry 2. Circ J. 2016;80(4):843–851.
   PubMed Web of Science ®Google Scholar
• Charlton B, Adeboyeje G, Barron JJ, et al. Length of hospital stay and all-cause mortality among adults with atrial fibrillation hospitalized for bleeding during treatment with warfarin, dabigatran, or rivaroxaban. Circulation. 2015;132(Suppl 3):A11583.
   Google Scholar
• Gorst-Rasmussen A, Lip GYH, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf. 2016;25(11):1236–1244.
   PubMed Web of Science ®Google Scholar
• Laliberte F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30(7):1317–1325.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Antz M, Bowrin K, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016;32(12):2047–2053.
   PubMed Web of Science ®Google Scholar
• Staerk L, Fosbøl EL, Lip GYH, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J. 2017;38(12):907–915.
   PubMed Web of Science ®Google Scholar
• Wong JM, Kennedy K, Shaw R. Comparing major bleeding risk in outpatients with atrial fibrillation by oral anticoagulant type: insights from the NCDR pinnacle registry. J Am Coll Cardiol. 2016;67(13 Suppl):666.
   Web of Science ®Google Scholar
• Nyman A, Collin JJKM, Borg N, et al. Safety of new anticoagulant treatments in Swedish patients with non-valvular atrial fibrillation. Pharmacoepidemiol Drug Saf. 2015;24:405.
   Web of Science ®Google Scholar
• Norby FL, Bengtson LG, Chen LY, et al. Comparative effectiveness of rivaroxaban versus warfarin for the treatment of patients with non-valvular atrial fibrillation. Circulation. 2016;133(Suppl 1):AP005 .
   Google Scholar
• Halvorsen S, Ghanima W, Fride Tvete I, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3(1):28–36.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Tangirala M, Evers T. Treatment persistence and discontinuation with rivaroxaban, dabigatran, and warfarin for stroke prevention in patients with non-valvular atrial fibrillation in the United States. PLoS One. 2016;11(6):e0157769.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18(8):1150–1157
   PubMed Web of Science ®Google Scholar
• Bengtson LGS, Lutsey PL, Chen LY, et al. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. J Cardiol. 2017;69(6):868–876.
   PubMed Web of Science ®Google Scholar
• Chan YH, Yen KC, See LC, et al. Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation. Stroke. 2016;47(2):441–449.
   PubMed Web of Science ®Google Scholar
• Chan PH, Huang D, Hai JJ, et al. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm. 2016;13(2):366–373.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–164.
   PubMed Web of Science ®Google Scholar
• Ho CW, Ho MH, Chan PH, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke. 2015;46(1):23–30.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med. 2014;127(12):1172–1178.
   PubMed Web of Science ®Google Scholar
• Li WH, Huang D, Chiang CE, et al. Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong atrial fibrillation project. Clin Cardiol. 2017;40(4):222–229.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61(22):2264–2273.
   PubMed Web of Science ®Google Scholar
• Luger S, Hohmann C, Niemann D, et al. Adherence to oral anticoagulant therapy in secondary stroke prevention - impact of the novel oral anticoagulants. Patient Prefer Adherence. 2015;9:1695–1705.
   PubMed Web of Science ®Google Scholar
• Nishtala PS, Gnjidic D, Jamieson HA, et al. Real-world’ haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand. Int J Cardiol. 2016;203:746–752.
   PubMed Web of Science ®Google Scholar
• Tsadok MA, Jackevicius CA, Essebag V, et al. Comparative effectiveness and safety of dabigatran vs. warfarin in patients with atrial fibrillation - evidence from real world practice. Circulation. 2013;128(22 Suppl):A13884.
   Web of Science ®Google Scholar
• Vaughan Sarrazin MS, Jones M, Mazur A, et al. Bleeding rates in veterans affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med. 2014;127(12):1179–1185.
   PubMed Web of Science ®Google Scholar
• Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114(6):1290–1298.
   PubMed Web of Science ®Google Scholar
• Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015;4(4):e001798.
   PubMed Web of Science ®Google Scholar
• Thelus R, Villines TC, Coster TS. Dabigatran versus warfarin among patients with atrial fibrillation: real-world post-market results. Circulation. 2012;126(Suppl 21):A14877.
   Web of Science ®Google Scholar
• Avgil Tsadok M, Jackevicius CA, Rahme E, et al. Sex differences in dabigatran use, safety, and effectiveness in a population-based cohort of patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015;8(6):593–599.
   PubMed Web of Science ®Google Scholar
• Alonso A, Chen LY, Maclehose RF, et al. Comparative effectiveness of dabigatran versus warfarin in patients with non-valvular atrial fibrillation. Circulation. 2013;128(Suppl 22):A14075.
   Web of Science ®Google Scholar
• Bengtson L, Chen L, Maclehose R, et al. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation. Circulation. 2014;130(Suppl 2):A20218.
   Google Scholar
• Chan PH, Huang D, Lau CP, et al. Net clinical benefit of dabigatran over warfarin in patients with atrial fibrillation stratified by CHA2DS2-VASc and time in therapeutic range. Can J Cardiol. 2016;32(10):1247.e1215–1247.e1221.
   Web of Science ®Google Scholar
• Hernandez I, Baik SH, Pinera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18–24.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014;127(7):650–656.e655.
   PubMed Web of Science ®Google Scholar
• Avgil-Tsadok M, Jackevicius CA, Essebag V, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost. 2016;115(1):152–160.
   PubMed Web of Science ®Google Scholar
• Agence Nationale de Sécurité du Médicament et des Produits de Santé. Study ‘in real life’ of the benefit/short-term risk of new oral anticoagulants (dabigatran, rivaroxaban) in patients starting treatment and not previously treated with oral anticoagulants. 2014. [ cited 2018 Apr 20] Available from: http://ansm.sante.fr/S-informer/Presse-Communiques-Points-presse/Surveillance-en-vie-reelle-des-anticoagulants-oraux-Communique. French.
   Google Scholar
• Ellis MH, Neuman T, Bitterman H, et al. Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: a retrospective population-based cohort study. Eur J Intern Med. 2016;33:55–59.
   PubMed Web of Science ®Google Scholar
• Korenstra J, Wijtvliet EP, Veeger NJ, et al. Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation. Europace. 2016;18(9):1319–1327.
   PubMed Web of Science ®Google Scholar
• Lip GY, Pan X, Kamble S, et al. Is major bleeding risk for oral anticoagulants similar among newly initiated non valvular atrial fibrillation patients? Circulation. 2015;132(Suppl 3):A19679.
   Google Scholar
• Seeger JD, Bartels DB, Huybrechts K, et al. Safety and effectiveness of dabigatran relative to warfarin in routine clinical practice-new interim results of long-term study program. Circulation. 2015;132(Suppl 3):A17137.
   Google Scholar
• Yavuz B, Ayturk M, Ozkan S, et al. A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation. J Thromb Thrombolysis. 2016;42(3):399–404.
   PubMed Web of Science ®Google Scholar
• Alpesh AN, Keshishian A, Xie L, et al. Early comparison of major bleeding, stroke and associated medical costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. Blood. 2015;126(23):745.
   Web of Science ®Google Scholar
• Amin A, Keshishian A, Xie L, et al. Comparison of major-bleeding risk and health care costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. Circulation. 2015;132(Suppl 3):A19672.
   Google Scholar
• Choi JC, Dibonaventura MD, Kopenhafer L, et al. Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. Patient Prefer Adherence. 2014;8:167–177.
   PubMed Web of Science ®Google Scholar
• Lin I, Masseria C, Mardekian J, et al. Real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, rivaroxaban and warfarin: analysis of electronic health records. Eur Heart J. 2015;36(Suppl 1):1084.
   Google Scholar
• Sørensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013;3(5):e002758.
   PubMed Web of Science ®Google Scholar
• Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes. 2013;6(5):567–574.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Lefevre C, Collings SL, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016;6(9):e011471.
   PubMed Web of Science ®Google Scholar
• Lau WCY, Chan EW, Wong ICK. Persistence of dabigatran versus warfarin therapy in patients with non-valvular atrial fibrillation in the real-world clinical practice. Pharmacoepidemiol Drug Saf. 2015;24(S1):382.
   Google Scholar
• Lip GYH, Pan X, Kamble S, et al. Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin. Eur Heart J. 2015;36(Suppl 1):1085.
   Google Scholar
• Lip G, Keshishian A, Kamble S, et al. Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, warfarin, dabigatran or rivaroxaban: a 1:1 propensity-score matched analysis. J Am Coll Cardiol. 2016;67(13 Suppl 1):882.
   Web of Science ®Google Scholar
• Lamberts M, Harboe L, Lefevre C, et al. Comparison of bleeding and treatment persistence among new users of novel oral anticoagulants and warfarin in patients with non-valvular atrial fibrillation. J Am Coll Cardiol. 2016;67(13 Suppl 1):887.
   Web of Science ®Google Scholar
• Deitelzweig S, Gupta K, Ogbonnaya A, et al. Compare major bleeding risk and associated costs among NVAF patients with CHA2DS2-VASc score > 3 newly anticoagulated with apixaban versus warfarin. J Am Coll Cardiol. 2016;67(13 Suppl 1):876.
   Web of Science ®Google Scholar